JP2013525416A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525416A5 JP2013525416A5 JP2013506743A JP2013506743A JP2013525416A5 JP 2013525416 A5 JP2013525416 A5 JP 2013525416A5 JP 2013506743 A JP2013506743 A JP 2013506743A JP 2013506743 A JP2013506743 A JP 2013506743A JP 2013525416 A5 JP2013525416 A5 JP 2013525416A5
- Authority
- JP
- Japan
- Prior art keywords
- nmn
- pharmaceutical composition
- modulator
- composition according
- degeneration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 claims 15
- 238000000034 method Methods 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 230000007850 degeneration Effects 0.000 claims 6
- KPBNHDGDUADAGP-VAWYXSNFSA-N FK-866 Chemical group C=1C=CN=CC=1/C=C/C(=O)NCCCCC(CC1)CCN1C(=O)C1=CC=CC=C1 KPBNHDGDUADAGP-VAWYXSNFSA-N 0.000 claims 4
- 102100033223 Nicotinamide phosphoribosyltransferase Human genes 0.000 claims 4
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 238000009007 Diagnostic Kit Methods 0.000 claims 3
- 239000012190 activator Substances 0.000 claims 3
- 230000003376 axonal effect Effects 0.000 claims 3
- 239000000090 biomarker Substances 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 238000011002 quantification Methods 0.000 claims 3
- 101100133505 Mus musculus Nmnat1 gene Proteins 0.000 claims 2
- 206010073696 Wallerian degeneration Diseases 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 2
- 230000003961 neuronal insult Effects 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 230000008734 wallerian degeneration Effects 0.000 claims 2
- BOIPLTNGIAPDBY-UHFFFAOYSA-N 2-[6-(4-chlorophenoxy)hexyl]-1-cyano-3-pyridin-4-ylguanidine Chemical compound C1=CC(Cl)=CC=C1OCCCCCCN=C(NC#N)NC1=CC=NC=C1 BOIPLTNGIAPDBY-UHFFFAOYSA-N 0.000 claims 1
- -1 6-chlorophenoxyhexyl Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012667 Diabetic glaucoma Diseases 0.000 claims 1
- 101150066466 NMNAT2 gene Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000005516 engineering process Methods 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 238000003317 immunochromatography Methods 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000005342 ion exchange Methods 0.000 claims 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 238000004452 microanalysis Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000004090 neuroprotective agent Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 239000003352 sequestering agent Substances 0.000 claims 1
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1006961.5A GB201006961D0 (en) | 2010-04-27 | 2010-04-27 | NMN modulator |
| GB1006961.5 | 2010-04-27 | ||
| PCT/GB2011/050770 WO2011135332A2 (en) | 2010-04-27 | 2011-04-19 | Nmn modulator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013525416A JP2013525416A (ja) | 2013-06-20 |
| JP2013525416A5 true JP2013525416A5 (enExample) | 2014-06-19 |
Family
ID=42270852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013506743A Abandoned JP2013525416A (ja) | 2010-04-27 | 2011-04-19 | 神経変性障害の治療のためのｎｍｎモジュレーター |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130131111A1 (enExample) |
| EP (1) | EP2563363A2 (enExample) |
| JP (1) | JP2013525416A (enExample) |
| AU (1) | AU2011247078A1 (enExample) |
| CA (1) | CA2796034A1 (enExample) |
| GB (1) | GB201006961D0 (enExample) |
| WO (1) | WO2011135332A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120328526A1 (en) * | 2011-06-27 | 2012-12-27 | University Of Maryland, Baltimore | Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof |
| CN103961691A (zh) * | 2013-02-03 | 2014-08-06 | 复旦大学 | 尼克酰胺磷酸核糖转移酶在制备神经保护药物中的用途 |
| CN104758307A (zh) * | 2015-03-16 | 2015-07-08 | 邦泰生物工程(深圳)有限公司 | Nadh和nmn在制备帕金森病药物或保健品的应用 |
| CA3123215C (en) * | 2018-12-19 | 2024-04-02 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with neuroprotective agents |
| US20220160688A1 (en) * | 2019-03-20 | 2022-05-26 | The Johns Hopkins University | Inhibition of nampt and/or sarm1 for the treatment of axonal degradation |
| JP2020156463A (ja) * | 2019-03-20 | 2020-10-01 | 株式会社リコー | インビトロで細胞を評価する方法、細胞基板、及び細胞基板の製造方法 |
| EP3712253A1 (en) * | 2019-03-20 | 2020-09-23 | Ricoh Company, Ltd. | Method of in vitro cellular assay, cell circuit board, and method of manufacturing cell circuit board |
| CN115605207A (zh) * | 2020-05-14 | 2023-01-13 | 葡默药物技术有限公司（Us） | 用于经粘膜给药的固体剂型 |
| CN112569289A (zh) * | 2020-12-24 | 2021-03-30 | 深圳市旷逸生物科技有限公司 | 一种含有nmn的帕金森治疗药物及其制备方法 |
| US12364681B2 (en) | 2021-01-08 | 2025-07-22 | The Johns Hopkins University | Combined MAPK and NAMPT inhibition for treatment of neuron degeneration |
| CN117582405A (zh) * | 2023-11-21 | 2024-02-23 | 广东药科大学 | 一种烟酰胺单核苷酸纳米复乳及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6797478B1 (en) * | 1998-03-05 | 2004-09-28 | University Of Cincinnati | Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies |
| CA2462632A1 (en) * | 2001-10-01 | 2003-04-10 | Emory University | Introduction of the wlds gene for prevention of axonal degeneration in neurological diseases |
| WO2003082187A2 (en) * | 2002-03-26 | 2003-10-09 | Indiana University | Purification and cloning of nmn adenylyltranserase and its therapeutic use |
| WO2004035823A2 (en) * | 2002-10-17 | 2004-04-29 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylytransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases |
| CN1964627B (zh) * | 2004-06-04 | 2011-10-19 | 华盛顿大学 | 治疗神经病变的方法和组合物 |
| WO2007136744A1 (en) * | 2006-05-19 | 2007-11-29 | The Johns Hopkins University | Crystal structure of a substrate complex of nampt/pbef/visfatin |
| WO2008026018A1 (en) * | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
| EP2098231A1 (en) * | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
| CN102186822A (zh) * | 2008-08-29 | 2011-09-14 | 顶标公司 | 新脲和硫脲衍生物 |
| GB0902147D0 (en) * | 2009-02-10 | 2009-03-25 | Babraham Inst | NMNAT2 modulator |
-
2010
- 2010-04-27 GB GBGB1006961.5A patent/GB201006961D0/en not_active Ceased
-
2011
- 2011-04-19 EP EP11715732A patent/EP2563363A2/en not_active Withdrawn
- 2011-04-19 US US13/643,997 patent/US20130131111A1/en not_active Abandoned
- 2011-04-19 CA CA2796034A patent/CA2796034A1/en not_active Abandoned
- 2011-04-19 WO PCT/GB2011/050770 patent/WO2011135332A2/en not_active Ceased
- 2011-04-19 AU AU2011247078A patent/AU2011247078A1/en not_active Abandoned
- 2011-04-19 JP JP2013506743A patent/JP2013525416A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011135332A4 (en) | Nmn modulators for the treatment of neurodegenerative disorders | |
| Oyaert et al. | Novel LC–MS/MS method for plasma vancomycin: Comparison with immunoassays and clinical impact | |
| Meredith Jr et al. | Characterization of novel CSF Tau and ptau biomarkers for Alzheimer’s disease | |
| Bowman et al. | Blood–brain barrier impairment in Alzheimer disease: stability and functional significance | |
| Lame et al. | Quantitation of amyloid beta peptides Aβ1–38, Aβ1–40, and Aβ1–42 in human cerebrospinal fluid by ultra-performance liquid chromatography–tandem mass spectrometry | |
| Van Dam et al. | Novel and sensitive reversed-phase high-pressure liquid chromatography method with electrochemical detection for the simultaneous and fast determination of eight biogenic amines and metabolites in human brain tissue | |
| Savage et al. | A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid | |
| Jozwiak et al. | Displacement and nonlinear chromatographic techniques in the investigation of interaction of noncompetitive inhibitors with an immobilized α3β4 nicotinic acetylcholine receptor liquid chromatographic stationary phase | |
| Encarnação et al. | Impact of assay temperature on antibody binding characteristics in living cells: A case study | |
| JP2016530504A5 (enExample) | ||
| Bros et al. | Quantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applications | |
| JP2016532689A5 (enExample) | ||
| WO2007117444A3 (en) | Protein detection by aptamers | |
| Galozzi et al. | Amyloid-β as a biomarker for Alzheimer’s disease: quantification methods in body fluids | |
| Rodrigues et al. | Structure-specific amyloid precipitation in biofluids | |
| Sano et al. | Absolute quantitation of low abundance plasma APL1β peptides at sub-fmol/mL level by SRM/MRM without immunoaffinity enrichment | |
| WO2014207049A3 (de) | Verfahren zur bestimmung von proteinaggregaten unter verwendung von oberflächen-fida | |
| WO2017027685A3 (en) | Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy | |
| JP2011122822A5 (enExample) | ||
| CN103822997A (zh) | 一种利伐沙班中间体的分析检测方法 | |
| Liu et al. | Stability of plasma amyloid-β 1–40, amyloid-β 1–42, and total tau protein over repeated freeze/thaw cycles | |
| WO2014202785A3 (de) | Schnelltest zum nachweisen von erregermaterial, insbesondere zur unterstützung der diagnose einer sepsis, sowie kit und vorrichtung zur durchführung eines sepsistests | |
| Dey et al. | Translating senotherapeutic interventions into the clinic with emerging proteomic technologies | |
| Younossi et al. | An exploratory study examining how nano-liquid chromatography–mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease | |
| Sun et al. | Aptamer-based sample purification for mass spectrometric quantification of trastuzumab in human serum |